文献速递白血病造血干细胞移植与细胞治疗

FLT3-ITD突变AML移植围术期分子MRD监测

Peritransplant molecular MRD monitoring by targeted NGS in patients with FLT3-ITD-mutated acute myeloid leukemia.
PubMed 文献 · Blood Adv · 2026-01-01

多中心回顾性研究纳入219例移植时形态学完全缓解的FLT3-ITD突变AML患者,用PCR-NGS评估围移植期MRD。移植前MRD阳性(≥0.001%)与较差的无复发生存、累积复发率和总生存相关;围移植期MRD动态优于单时间点评估;移植后FLT3抑制剂维持独立改善RFS。

要点

  • 移植前PCR-NGS MRD阳性(≥0.001%)者2年RFS、累积复发率和OS均显著劣于MRD阴性者。
  • 围移植期MRD动态评估优于单时间点,可识别移植后MRD转阳等高危患者。
  • 移植后FLT3抑制剂维持独立改善RFS,MRD阳性患者获益最大。

核心结论

  • PCR-NGS分子MRD评估可优化FLT3-ITD突变AML移植风险分层并指导个体化移植策略。

研究设计与样本

  • 多中心回顾性研究,纳入219例移植时形态学完全缓解的FLT3-ITD突变AML患者,用PCR-NGS评估围移植期MRD。

主要发现

  • 移植前MRD阳性(≥0.001%)对比阴性:2年RFS 56.8% vs 86.5%,累积复发率30.0% vs 6.9%,OS 65.9% vs 88.4%,均P< .001。
  • 围移植期MRD动态优于单时间点评估,可识别移植后MRD转阳等高危患者。
  • 移植后FLT3抑制剂维持独立改善RFS(P = .003),MRD阳性患者获益最大。

关键数值与推荐

  • 移植前MRD阳性阈值定义为PCR-NGS检测≥0.001%。
  • 移植前MRD阳性者2年RFS 56.8%、累积复发率30.0%、OS 65.9%;MRD阴性者分别为86.5%、6.9%、88.4%。

临床怎么用

  • 对FLT3-ITD突变AML移植患者,可考虑用PCR-NGS进行围移植期分子MRD动态监测以细化风险分层。
  • 移植后MRD转阳等高危患者可考虑FLT3抑制剂维持治疗以改善RFS。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Relapse is the predominant cause of treatment failure after allogeneic hematopoietic cell transplantation (HCT) in FLT3 gene internal tandem duplication (FLT3-ITD)-mutated acute myeloid leukemia (AML). Although measurable residual disease (MRD) is increasingly used for risk stratification, optimal FLT3-ITD MRD assessment, the prognostic value of peritransplant MRD dynamics, and their implications in transplant-related decision-making remain unclear. We conducted a multicenter, retrospective study of 219 patients with FLT3-ITD-mutated AML in morphologic complete remission at transplantation, assessing peritransplant MRD by polymerase chain reaction (PCR)-next-generation sequencing (NGS). Pretransplant MRD positivity (≥0.001% by PCR-NGS) was associated with inferior outcomes vs MRD negativity (2-year relapse-free survival [RFS], 56.8% vs 86.5%; cumulative incidence of relapse, 30.0% vs 6.9%; overall survival, 65.9% vs 88.4%; all P< .001). Peritransplant MRD dynamics outperformed single time point assessments, identifying patients at high risk such as those with post-HCT MRD conversion. Post-HCT FLT3 inhibitor maintenance independently improved RFS (P = .003), with greatest benefit observed in patients who were MRD-positive. These findings support PCR-NGS-based molecular MRD assessment to refine risk stratification and guide individualized transplant strategies in FLT3-ITD-mutated AML.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Hu X, Zhao Y, Jiang C, et al. Peritransplant molecular MRD monitoring by targeted NGS in patients with FLT3-ITD-mutated acute myeloid leukemia. Blood Adv. 2026. PMID: 42263741. doi:10.1182/bloodadvances.2026020264

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。